PDL BioPharma (PDLI) Balance Sheet

Click line-items for a historical chart and %

Cash and cash equivalents	106.59M
Short-term investments
Receivables from licensees	26.04M
Deferred tax assets
Foreign currency hedge
Prepaid and other current assets	973K
Total current assets	355.06M
Property and equipment, net	16K
Long-term investments
Long-term deferred tax assets	24.23M
Other assets	9M
Total assets	1.22B
Accounts payable	7.13M
Accrued legal settlement
Accrued liabilities	9.48M
Accrued income taxes
Foreign currency hedge
Deferred revenue	11.61M
Dividend payable
Current portion of non-recourse notes payable
Total current liabilities	121.51M
Convertible notes payable	234.9M
Non-recourse notes payable
Other long-term liabilities	56.85M
Total liabilities	462.21M
Commitments and contingencies (Note 13)	0
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding	0
Common stock, par value $0.01 per share, 250,000 shares authorized; 139,795 and 139,640 issued and outstanding at June 30, 2011, and December 31, 2010, respectively	1.66M
Additional paid-in capital	-119.47M
Accumulated other comprehensive income	3K
Accumulated deficit	867.44M
Total stockholders' deficit	749.63M
Total liabilities and stockholders' deficit	1.22B

Entities mentioned with PDLI

View All Entities